Searched for
ORAL OBESITY DRUGS
From Jab to Pills: Novo Nordisk, Eli Lilly set to take obesity drug battle to IndiaIndia’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to la...- UK first in Europe to approve Eli Lilly oral weight loss drugBritain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...
- Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetesBritain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...
- Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipelineNovo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...
- Type 2 diabetes patients on metformin, take note: After 60 years, scientists find this drug has hidden effects on the brainDiabetes: Recent studies reveal that metformin may influence blood sugar management via the brain. This medication stimulates a distinct br...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Obesity drug market to gain as Indians pop the pill and Chinese bring moreIndia's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, w...
- Ahead of its time, a GLP-1 drug almost made it out of IndiaFifteen years back, Zydus Lifesciences introduced ZYOG1, an oral GLP-1 agonist that sparked excitement for its implications in diabetes man...
- Future diabetes care seen leaning towards GLP-1 drugsThe diabetes treatment landscape in India is on the brink of transformation. Innovative GLP-1 medications are set to redefine therapy stand...
- Weight-loss treatment: How has obesity medicine market become battleground for pharma giants like Pfizer, AstraZeneca, Eli Lilly?Obesity, weight-loss medicines: Novo has been scrambling to keep pace in the obesity drug race it started, losing ground to rival Eli Lilly...
- Eli Lilly Q2 earnings beat expectations on Mounjaro, Zepbound sales, stock falls after obesity drug trial missLilly stock latest news: Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year gu...
- Obesity drugs gain weight in labs: Several clinical trials by big and small pharma cos underwayDriven by the success of Wegovy and Mounjaro, numerous pharma companies are developing anti-obesity drugs, with over 170 in various stages....
- Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launchEli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participant...
- New oral diabetes + obesity drug's India sales surge 100%India experiences a surge in Rybelsus sales, impacting the anti-obesity market. Semaglutide dominates, reflecting India's obesity challenge...
- Eli Lilly in advanced clinical trials for its weight-loss pillEli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess ...
- Anti-obesity drug market gaining traction in IndiaAccording to research firm Pharmarack, the market has tripled in two years after witnessing a sluggish growth till 2021. Over the last five...
- Say goodbye to needle pricks! A daily pill may be cure to world's obesity problemNovo Nordisk's weight-loss drug, Wegovy, which has so far only been available as an injection, may soon come in pill form. Clinical trials ...
- Novo Nordisk launches anti-diabetes pill semaglutide in IndiaNovo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in India for treatment of type 2 diabetes.
- Zydus Cadila gets USFDA nod to market anti-obesity drugThe product is used together with diet and exercise to treat obesity (overweight) in people with risk factors such as high blood pressure, ...
Load More
